SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 - PubMed (original) (raw)
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7
Gareth J Inman et al. Mol Pharmacol. 2002 Jul.
Abstract
Small molecule inhibitors have proven extremely useful for investigating signal transduction pathways and have the potential for development into therapeutics for inhibiting signal transduction pathways whose activities contribute to human diseases. Transforming growth factor beta (TGF-beta) is a member of a large family of pleiotropic cytokines that are involved in many biological processes, including growth control, differentiation, migration, cell survival, adhesion, and specification of developmental fate, in both normal and diseased states. TGF-beta superfamily members signal through a receptor complex comprising a type II and type I receptor, both serine/threonine kinases. Here, we characterize a small molecule inhibitor (SB-431542) that was identified as an inhibitor of activin receptor-like kinase (ALK)5 (the TGF-beta type I receptor). We demonstrate that it inhibits ALK5 and also the activin type I receptor ALK4 and the nodal type I receptor ALK7, which are very highly related to ALK5 in their kinase domains. It has no effect on the other, more divergent ALK family members that recognize bone morphogenetic proteins (BMPs). Consistent with this, we demonstrate that SB-431542 is a selective inhibitor of endogenous activin and TGF-beta signaling but has no effect on BMP signaling. To demonstrate the specificity of SB-431542, we tested its effect on several other signal transduction pathways whose activities depend on the concerted activation of multiple kinases. SB-431542 has no effect on components of the ERK, JNK, or p38 MAP kinase pathways or on components of the signaling pathways activated in response to serum.
Similar articles
- SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S, Major C, Laping NJ, Roberts AB. DaCosta Byfield S, et al. Mol Pharmacol. 2004 Mar;65(3):744-52. doi: 10.1124/mol.65.3.744. Mol Pharmacol. 2004. PMID: 14978253 - Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S, Klein C, Roh J, Kaivo-Oja N, Mottershead DG, Korchynskyi O, Ritvos O, Hsueh AJ. Mazerbourg S, et al. Mol Endocrinol. 2004 Mar;18(3):653-65. doi: 10.1210/me.2003-0393. Epub 2003 Dec 18. Mol Endocrinol. 2004. PMID: 14684852 - The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T. Tojo M, et al. Cancer Sci. 2005 Nov;96(11):791-800. doi: 10.1111/j.1349-7006.2005.00103.x. Cancer Sci. 2005. PMID: 16271073 Free PMC article. - Bone morphogenetic proteins.
Chen D, Zhao M, Mundy GR. Chen D, et al. Growth Factors. 2004 Dec;22(4):233-41. doi: 10.1080/08977190412331279890. Growth Factors. 2004. PMID: 15621726 Review. - Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Tsuchida K, et al. Endocr J. 2008 Mar;55(1):11-21. doi: 10.1507/endocrj.kr-110. Epub 2007 Sep 14. Endocr J. 2008. PMID: 17878607 Review.
Cited by
- Olanzapine enhances early brain maturation through activation of the NODAL/FOXH1 axis.
Teng Z, Chen Z, Zou T, Su Y, Zeng H, Sun S, Chen H, Liu J, Qin Y, Wu H, Chen J, Liu F, Wu R, Huang J. Teng Z, et al. iScience. 2024 Sep 11;27(10):110917. doi: 10.1016/j.isci.2024.110917. eCollection 2024 Oct 18. iScience. 2024. PMID: 39474064 Free PMC article. - Suppressing PDGFRβ Signaling Enhances Myocyte Fusion to Promote Skeletal Muscle Regeneration.
Xue S, Benvie AM, Blum JE, Kolba NJ, Cosgrove BD, Thalacker-Mercer A, Berry DC. Xue S, et al. bioRxiv [Preprint]. 2024 Oct 18:2024.10.15.618247. doi: 10.1101/2024.10.15.618247. bioRxiv. 2024. PMID: 39464006 Free PMC article. Preprint. - Human transforming growth factor β type I receptor in complex with kinase inhibitor SB505124.
Rodriguez Buitrago JA, Landström M, Wolf-Watz M. Rodriguez Buitrago JA, et al. Acta Crystallogr F Struct Biol Commun. 2024 Nov 1;80(Pt 11):314-319. doi: 10.1107/S2053230X24010094. Epub 2024 Oct 23. Acta Crystallogr F Struct Biol Commun. 2024. PMID: 39441620 Free PMC article. - Growth differentiation factor 11 alleviates oxidative stress-induced senescence of endothelial progenitor cells via activating autophagy.
Tao P, Zhang HF, Zhou P, Wang YL, Tan YZ, Wang HJ. Tao P, et al. Stem Cell Res Ther. 2024 Oct 17;15(1):370. doi: 10.1186/s13287-024-03975-y. Stem Cell Res Ther. 2024. PMID: 39420391 Free PMC article. - The Neuroanatomy of Induced Pluripotent Stem Cells: In Vitro Models of Subcortical Nuclei in Neurodegenerative Disorders.
Galgani A, Scotto M, Giorgi FS. Galgani A, et al. Curr Issues Mol Biol. 2024 Sep 14;46(9):10180-10199. doi: 10.3390/cimb46090607. Curr Issues Mol Biol. 2024. PMID: 39329959 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous